Table 1.
Patient clinicopathologic characteristics before and after propensity score matching analysis.
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| r-CEA <5 (n = 534) | r-CEA ≥5 (n = 428) | p | r-CEA <5 (n = 389) | r-CEA ≥5 (n = 389) | p | |
| Age, years, median (SD) | 60 ± 13 | 61 ± 13 | 0.680 | 60 ± 13 | 61 ± 12 | 0.392 |
| Sex, n (%) | 0.514 | 0.770 | ||||
| Male Female |
323 (60.5) 211 (39.5) |
250 (58.4) 178 (41.6) |
233 (59.9) 156 (40.1) |
229 (58.9) 160 (41.1) |
||
| Initial CEA (ng/mL) | <0.001 | 0.203 | ||||
| Normal (<5) High (>5) |
406 (76.0) 128 (24.0) |
279 (65.2) 149 (34.8) |
287 (73.8) 102 (26.2) |
270 (69.4) 119 (30.6) |
||
| Initial tumor location, n (%) | 0.105 | 0.498 | ||||
| Colon Rectum |
326 (61.0) 208 (39.0) |
283 (66.1) 145 (33.9) |
250 (64.3) 139 (35.7) |
259 (66.6) 130 (33.4) |
||
| Initial TNM stage, n (%) | <0.001 | 1.000 | ||||
| I II III |
68 (12.7) 144 (27.0) 322 (60.3) |
14 (3.3) 71 (16.6) 343 (80.1) |
14 (3.6) 70 (18.0) 305 (78.4) |
14 (3.6) 70 (18.0) 305 (78.4) |
||
| Initial pathologic T stage, n (%) | <0.001 | 0.610 | ||||
| T1 T2 T3 T4 |
41 (7.7) 46 (8.6) 303 (56.7) 144 (27.0) |
12 (2.8) 17 (4.0) 279 (65.2) 120 (28.0) |
10 (2.6) 22 (5.7) 239 (61.4) 118 (30.3) |
10 (2.6) 15 (3.9) 252 (64.8) 112 (28.7) |
||
| Initial pathologic N stage, n (%) | <0.001 | 0.672 | ||||
| N0 N1 N2 |
212 (39.7) 147 (27.5) 175 (32.8) |
85 (19.9) 164 (38.3) 179 (41.8) |
84 (21.6) 138 (35.5) 167 (42.9) |
84 (21.6) 149 (38.3) 156 (40.1) |
||
| Initial size of tumor (cm, SD) | 4.7 ± 3.0 | 5.1 ± 2.2 | 0.076 | 5.0 ± 3.1 | 5.1 ± 2.2 | 0.784 |
| Initial cell differentiation, n (%) | 0.293 | 0.922 | ||||
| WD+MD PD+MUC+SRC |
462 (86.5) 72 (13.5) |
360 (84.1) 68 (15.9) |
327 (84.1) 62 (15.9) |
328 (84.3) 61 (15.7) |
||
| Initial lymphatic invasion, n (%) | 0.004 | 0.565 | ||||
| (+) (-) |
245 (45.9) 289 (54.1) |
236 (55.1) 192 (44.9) |
213 (54.8) 176 (45.2) |
205 (52.7) 184 (47.3) |
||
| Initial venous invasion, n (%) | 0.422 | 0.393 | ||||
| (+) (-) |
152 (28.5) 382 (71.5) |
132 (30.8) 296 (69.2) |
125 (32.1) 264 (67.9) |
114 (29.3) 275 (70.7) |
||
| Initial perineural invasion, n (%) | 0.042 | 0.705 | ||||
| (+) (-) |
158 (29.6) 376 (70.4) |
153 (35.7) 275 (64.3) |
135 (34.7) 254 (65.3) |
130 (33.4) 259 (66.6) |
||
| Initial tumor budding, n (%) | 0.048 | 0.828 | ||||
| (+) (-) |
274 (51.3) 260 (48.7) |
247 (57.7) 181 (42.3) |
222 (57.1) 167 (42.9) |
219 (56.3) 170 (43.7) |
||
| MSI | 0.698 | 0.521 | ||||
| MSS MSI-H MSI-L |
505 (94.6) 21 (3.9) 8 (1.5) |
402 (93.9) 21 (4.9) 5 (1.2) |
372 (95.6) 13 (3.3) 4 (1.0) |
365 (93.8) 19 (4.9) 5 (1.3) |
||
| KRAS | 0.360 | 0.963 | ||||
| Wild type Mutation type Not identification |
385 (72.1) 88 (16.5) 61 (11.4) |
311 (72.6) 79 (18.5) 38 (8.9) |
276 (71.0) 74 (19.0) 39 (10.0) |
279 (71.7) 73 (18.8) 37 (9.5) |
||
| Median disease-free interval, months | 19.8 ± 15.4 | 17.7 ± 14.4 | 0.027 | 18.7 ± 14.0 | 17.8 ± 14.9 | 0.374 |
| Treatment after recurrence, n (%) | 0.625 | 0.764 | ||||
| Salvage treatment Surgery +/- CTx, RTx CTx or RTx or CCRT only Conservative treatment |
439 (82.2) 205 (38.4) 234 (43.8) 95 (17.8) |
358 (83.7) 177 (41.4) 181 (42.3) 70 (16.3) |
329 (84.6) 141 (36.3) 188 (48.3) 60 (15.4) |
324 (83.3) 132 (33.9) 192 (49.4) 65 (16.7) |
||
CEA, carcinoembryonic antigen; r-CEA, CEA level at the time of recurrence; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; MUC, mucinous adenocarcinoma; SRC, signet ring cell carcinoma; MSS, microsatellite stable; MSI-L, microsatellite instability low; MSI-H, microsatellite instability high; CTx, chemotherapy; RTx, radiotherapy.